Search

Your search keyword '"Goldberg, A."' showing total 1,688 results
Start Over Author "Goldberg, A." Journal blood
1,688 results on '"Goldberg, A."'

1. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Author

Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad Z., Bahlis, Nizar J., van de Donk, Niels W. C. J., and Verona, Raluca I.

Published
2024
Full Text
View/download PDF

2. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Author

Shalabi, Haneen, Qin, Haiying, Su, Angela, Yates, Bonnie, Wolters, Pamela L., Steinberg, Seth M., Ligon, John A., Silbert, Sara, DéDé, Kniya, Benzaoui, Mehdi, Goldberg, Sophia, Achar, Sooraj, Schneider, Dina, Shahani, Shilpa A., Little, Lauren, Foley, Toni, Molina, John C., Panch, Sandhya, Mackall, Crystal L., Lee, Daniel W., Chien, Christopher D., Pouzolles, Marie, Ahlman, Mark, Yuan, Constance M., Wang, Hao-Wei, Wang, Yanyu, Inglefield, Jon, Toledo-Tamula, Mary Anne, Martin, Staci, Highfill, Steven L., Altan-Bonnet, Gregoire, Stroncek, David, Fry, Terry J., Taylor, Naomi, and Shah, Nirali N.

Published
2022
Full Text
View/download PDF

3. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Author

Mascarenhas, John, Kosiorek, Heidi E., Prchal, Josef T., Rambaldi, Alessandro, Berenzon, Dmitriy, Yacoub, Abdulraheem, Harrison, Claire N., McMullin, Mary Frances, Vannucchi, Alessandro M., Ewing, Joanne, O'Connell, Casey L., Kiladjian, Jean-Jacques, Mead, Adam J., Winton, Elliott F., Leibowitz, David S., De Stefano, Valerio, Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Levine, Max F., Arango Ossa, Juan E., McGovern, Erin, Sandy, Lonette, Salama, Mohamad E., Najfeld, Vesna, Tripodi, Joseph, Farnoud, Noushin, Penson, Alexander V., Weinberg, Rona Singer, Price, Leah, Goldberg, Judith D., Barbui, Tiziano, Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Dueck, Amylou C., and Hoffman, Ronald

Published
2022
Full Text
View/download PDF

4. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Author

Cortes, Jorge E, Tallman, Martin S, Schiller, Gary J, Trone, Denise, Gammon, Guy, Goldberg, Stuart L, Perl, Alexander E, Marie, Jean-Pierre, Martinelli, Giovanni, Kantarjian, Hagop M, and Levis, Mark J

Subjects
Clinical Research, Rare Diseases, Hematology, Childhood Leukemia, Pediatric Research Initiative, Clinical Trials and Supportive Activities, Cancer, Pediatric, Pediatric Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, Benzothiazoles, Dose-Response Relationship, Drug, Female, Gastrointestinal Diseases, Gene Duplication, Heart Diseases, Hematologic Diseases, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Male, Middle Aged, Oncogene Proteins, Fusion, Phenylurea Compounds, Protein Kinase Inhibitors, Salvage Therapy, Tandem Repeat Sequences, Young Adult, fms-Like Tyrosine Kinase 3, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

This randomized, open-label, phase 2b study (NCT01565668) evaluated the efficacy and safety of 2 dosing regimens of quizartinib monotherapy in patients with relapsed/refractory (R/R) FLT3-internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML) who previously underwent transplant or 1 second-line salvage therapy. Patients (N = 76) were randomly assigned to 30- or 60-mg/day doses (escalations to 60 or 90 mg/day, respectively, permitted for lack/loss of response) of single-agent oral quizartinib dihydrochloride. Allelic frequency of at least 10% was defined as FLT3-ITD-mutated disease. Coprimary endpoints were composite complete remission (CRc) rates and incidence of QT interval corrected by Fridericia's formula (QTcF) of more than 480 ms (grade 2 or greater). Secondary endpoints included overall survival (OS), duration of CRc, bridge to transplant, and safety. CRc rates were 47% in both groups, similar to earlier reports with higher quizartinib doses. Incidence of QTcF above 480 ms was 11% and 17%, and QTcF above 500 ms was 5% and 3% in the 30- and 60-mg groups, respectively, which is less than earlier reports with higher doses of quizartinib. Median OS (20.9 and 27.3 weeks), duration of CRc (4.2 and 9.1 weeks), and bridge to transplant rates (32% and 42%) were higher in the 60-mg groups than in the 30-mg group. Dose escalation occurred in 61% and 14% of patients in the 30- and 60-mg groups, respectively. This high clinical activity of quizartinib at the evaluated doses is consistent with previous reports with an improved safety profile. Need to dose-escalate more than half of patients who received quizartinib 30 mg also supports further investigation of treatment with quizartinib 60 mg/day.

Published
2018

5. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

Author

Xiao, Wenbin, Chan, Alexander, Waarts, Michael R., Mishra, Tanmay, Liu, Ying, Cai, Sheng F., Yao, Jinjuan, Gao, Qi, Bowman, Robert L., Koche, Richard P., Csete, Isabelle S., DelGaudio, Nicole L., Derkach, Andriy, Baik, Jeeyeon, Yanis, Sophia, Famulare, Christopher A., Patel, Minal, Arcila, Maria E., Stahl, Maximilian, Rampal, Raajit K., Tallman, Martin S., Zhang, Yanming, Dogan, Ahmet, Goldberg, Aaron D., Roshal, Mikhail, and Levine, Ross L.

Published
2021
Full Text
View/download PDF

6. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Author

Yacoub, Abdulraheem, Mascarenhas, John, Kosiorek, Heidi, Prchal, Josef T., Berenzon, Dmitry, Baer, Maria R., Ritchie, Ellen, Silver, Richard T., Kessler, Craig, Winton, Elliott, Finazzi, Maria Chiara, Rambaldi, Alessandro, Vannucchi, Alessandro M., Leibowitz, David, Rondelli, Damiano, Arcasoy, Murat O., Catchatourian, Rosalind, Vadakara, Joseph, Rosti, Vittorio, Hexner, Elizabeth, Kremyanskaya, Marina, Sandy, Lonette, Tripodi, Joseph, Najfeld, Vesna, Farnoud, Noushin, Papaemmanuil, Elli, Salama, Mohamed, Singer-Weinberg, Rona, Rampal, Raajit, Goldberg, Judith D., Barbui, Tiziano, Mesa, Ruben, Dueck, Amylou C., and Hoffman, Ronald

Published
2019
Full Text
View/download PDF

8. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis

Author

Chinn, Ivan K., Eckstein, Olive S., Peckham-Gregory, Erin C., Goldberg, Baruch R., Forbes, Lisa R., Nicholas, Sarah K., Mace, Emily M., Vogel, Tiphanie P., Abhyankar, Harshal A., Diaz, Maria I., Heslop, Helen E., Krance, Robert A., Martinez, Caridad A., Nguyen, Trung C., Bashir, Dalia A., Goldman, Jordana R., Stray-Pedersen, Asbjørg, Pedroza, Luis A., Poli, M. Cecilia, Aldave-Becerra, Juan C., McGhee, Sean A., Al-Herz, Waleed, Chamdin, Aghiad, Coban-Akdemir, Zeynep H., Jhangiani, Shalini N., Muzny, Donna M., Cao, Tram N., Hong, Diana N., Gibbs, Richard A., Lupski, James R., Orange, Jordan S., McClain, Kenneth L., and Allen, Carl E.

Published
2018
Full Text
View/download PDF

9. Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Author

Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Christoph Heuck, Jesús San-Miguel, and Philippe Moreau

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

10. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Author

Haneen Shalabi, Haiying Qin, Angela Su, Bonnie Yates, Pamela L. Wolters, Seth M. Steinberg, John A. Ligon, Sara Silbert, Kniya DéDé, Mehdi Benzaoui, Sophia Goldberg, Sooraj Achar, Dina Schneider, Shilpa A. Shahani, Lauren Little, Toni Foley, John C. Molina, Sandhya Panch, Crystal L. Mackall, Daniel W. Lee, Christopher D. Chien, Marie Pouzolles, Mark Ahlman, Constance M. Yuan, Hao-Wei Wang, Yanyu Wang, Jon Inglefield, Mary Anne Toledo-Tamula, Staci Martin, Steven L. Highfill, Gregoire Altan-Bonnet, David Stroncek, Terry J. Fry, Naomi Taylor, and Nirali N. Shah

Subjects
Lymphoma, B-Cell, Receptors, Chimeric Antigen, T-Lymphocytes, Antigens, CD19, Immunology, Receptors, Antigen, T-Cell, Cell Biology, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma, Immunotherapy, Adoptive, Biochemistry, Mice, Recurrence, Animals, Cytokines, Humans, Cytokine Release Syndrome
Abstract

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute lymphoblastic leukemia (B-ALL), we report on our phase 1 dose-escalation study of a novel murine stem cell virus (MSCV)-CD19/CD22-4-1BB bivalent CAR T-cell (CD19.22.BBζ) for children and young adults (CAYA) with B-cell malignancies. Primary objectives included toxicity and dose finding. Secondary objectives included response rates and relapse-free survival (RFS). Biologic correlatives included laboratory investigations, CAR T-cell expansion and cytokine profiling. Twenty patients, ages 5.4 to 34.6 years, with B-ALL received CD19.22.BBζ. The complete response (CR) rate was 60% (12 of 20) in the full cohort and 71.4% (10 of 14) in CAR-naïve patients. Ten (50%) developed cytokine release syndrome (CRS), with 3 (15%) having ≥ grade 3 CRS and only 1 experiencing neurotoxicity (grade 3). The 6- and 12-month RFS in those achieving CR was 80.8% (95% confidence interval [CI]: 42.4%-94.9%) and 57.7% (95% CI: 22.1%-81.9%), respectively. Limited CAR T-cell expansion and persistence of MSCV-CD19.22.BBζ compared with EF1α-CD22.BBζ prompted laboratory investigations comparing EF1α vs MSCV promoters, which did not reveal major differences. Limited CD22 targeting with CD19.22.BBζ, as evaluated by ex vivo cytokine secretion and leukemia eradication in humanized mice, led to development of a novel bicistronic CD19.28ζ/CD22.BBζ construct with enhanced cytokine production against CD22. With demonstrated safety and efficacy of CD19.22.BBζ in a heavily pretreated CAYA B-ALL cohort, further optimization of combinatorial antigen targeting serves to overcome identified limitations (www.clinicaltrials.gov #NCT03448393).

Published
2022

11. Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Author

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, and Andrew Spencer

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

12. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Author

Diana Cortes-Selva, Tineke Casneuf, Deeksha Vishwamitra, Sarah Stein, Tatiana Perova, Sheri Skerget, Elena Ramos, Laure van Steenbergen, Dries De Maeyer, Rengasamy Boominathan, Onsay Lau, Cuc Davis, Arnob Banerjee, Tara Stephenson, Clarissa M. Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Usmani, Nizar Jacques Bahlis, Niels WCJ Van De Donk, and Raluca Verona

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

13. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, and Mark R. Litzow

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

15. Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Author

Eric S. Winer, Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, Adam S Duvall, Yasmin Abaza, Timothy Seijung Oh, Karen Ma, Talha Badar, Mark R. Litzow, Vamsi Kota, Danielle Bradshaw, Hari S. Raman, Marlise R. Luskin, Richard M. Stone, and Daniel J. DeAngelo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

17. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, and Mark R. Litzow

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

18. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Author

Cyrille Touzeau, Ajai Chari, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Kelly Kato, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Chris Heuck, Philippe Moreau, and Jesús San-Miguel

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

23. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation

Author

Ponce, Doris M., Hilden, Patrick, Mumaw, Christen, Devlin, Sean M., Lubin, Marissa, Giralt, Sergio, Goldberg, Jenna D., Hanash, Alan, Hsu, Katharine, Jenq, Robert, Perales, Miguel-Angel, Sauter, Craig, van den Brink, MarcelR. M., Young, James W., Brentjens, Renier, Kernan, Nancy A., Prockop, Susan E., O’Reilly, Richard J., Scaradavou, Andromachi, Paczesny, Sophie, and Barker, Juliet N.

Published
2015
Full Text
View/download PDF

24. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia

Author

Przespolewski, Amanda, primary, Goldberg, Aaron D, additional, Talati, Chetasi, additional, Fazal, Salman, additional, Vachhani, Pankit, additional, Sanikommu, Srinivasa Reddy, additional, Thota, Swapna, additional, Waksal, Julian A., additional, Ball, Brian John, additional, Famulare, Christopher A, additional, Stahl, Maximilian, additional, Baron, Jeffrey, additional, Griffiths, Elizabeth A, additional, Thompson, James E., additional, Sweet, Kendra L, additional, and Wang, Eunice S., additional

Published
2022
Full Text
View/download PDF

25. Safety and efficacy of CPX-351 in younger patients (

Author

Przespolewski, Amanda, Goldberg, Aaron D., Talati, Chetasi, Fazal, Salman, Vachhani, Pankit, Sanikommu, Srinivasa R., Thota, Swapna, Waksal, Julian, Ball, Brian, Famulare, Christopher, Stahl, Maximilian, Baron, Jeffrey, Griffiths, Elizabeth A., Thompson, James E., Sweet, Kendra, and Wang, Eunice S.

Published
2023
Full Text
View/download PDF

26. Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Author

Winer, Eric S., primary, Flamand, Yael, additional, Shallis, Rory Michael, additional, Stempel, Jessica M., additional, Goldberg, Aaron D, additional, Stahl, Maximilian F., additional, Patel, Anand Ashwin, additional, Duvall, Adam S, additional, Abaza, Yasmin, additional, Seijung Oh, Timothy, additional, Ma, Karen, additional, Badar, Talha, additional, Litzow, Mark R., additional, Kota, Vamsi, additional, Bradshaw, Danielle, additional, Raman, Hari S., additional, Luskin, Marlise R., additional, Stone, Richard M., additional, and DeAngelo, Daniel J., additional

Published
2022
Full Text
View/download PDF

27. A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Author

Goldberg, Aaron D, primary, Ohanian, Maro, additional, Koller, Paul B., additional, Cherry, Mohamad, additional, Altman, Jessica K., additional, Tomlinson, Benjamin, additional, Chandhok, Namrata Sonia, additional, Nguyen Haney, Donna, additional, Hu, Jia, additional, Sinha, Ranjeet Kumar, additional, Rice, William G, additional, and Bejar, Rafael, additional

Published
2022
Full Text
View/download PDF

28. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Author

Touzeau, Cyrille, primary, Chari, Ajai, additional, Schinke, Carolina, additional, Minnema, Monique C., additional, Berdeja, Jesus, additional, Oriol, Albert, additional, Van De Donk, Niels WCJ, additional, Rodriguez Otero, Paula, additional, Askari, Elham, additional, Mateos, Maria-Victoria, additional, Costa, Luciano J., additional, Caers, Jo, additional, Rasche, Leo, additional, Krishnan, Amrita Y., additional, Vishwamitra, Deeksha, additional, Ma, Xuewen, additional, Qin, Xiang, additional, Gries, Katharine S., additional, Kato, Kelly, additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Goldberg, Jenna D., additional, Heuck, Chris, additional, Moreau, Philippe, additional, and San-Miguel, Jesús, additional

Published
2022
Full Text
View/download PDF

29. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Shallis, Rory Michael, additional, Saliba, Antoine N., additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Grenet, Justin, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Kubiak, Michal Jakub, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

30. Quantitative Cytogenetic Analysis with karyoParser Allows for More Precise Identification of Disease Biology, Clonal Evolution, and Etiology of Relapse in Acute Myeloid Leukemia

Author

Dilip, Deepika, primary, Derkach, Andriy, additional, Menghrajani, Kamal, additional, Goldberg, Aaron D, additional, May, Hannah, additional, Klimek, Virginia M., additional, Galera, Pallavi K, additional, Xiao, Wenbin, additional, Zhang, Yanming, additional, Elemento, Olivier, additional, Levine, Ross L., additional, and Glass, Jacob L, additional

Published
2022
Full Text
View/download PDF

31. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Author

Miao, Xin, primary, Wu, Liviawati S., additional, Wang Lin, Shun Xin, additional, Xu, Yan, additional, Chen, Yang, additional, Iwaki, Yuki, additional, Kobos, Rachel, additional, Stephenson, Tara, additional, Kemmerer, Kristy, additional, Uhlar, Clarissa M., additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Pei, Lixia, additional, Su, Yaming, additional, Ouellet, Daniele, additional, Garfall, Alfred L., additional, Krishnan, Amrita Y., additional, Usmani, Saad, additional, Girgis, Suzette, additional, and Zhou, Honghui, additional

Published
2022
Full Text
View/download PDF

32. Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Author

Mauro, Michael, primary, Paquette, Ronald, additional, Hehlmann, Rüdiger, additional, Williams, Loretta A., additional, Goldberg, Stuart L., additional, Michallet, Mauricette, additional, Gambacorti-Passerini, Carlo, additional, Tang, Derek, additional, DeGutis, Irene S., additional, McBride, Ali, additional, Parsons, Lori, additional, Montelongo, Monica Z., additional, and Cortes, Jorge E., additional

Published
2022
Full Text
View/download PDF

33. Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Author

Cortes, Jorge E., primary, Goldberg, Stuart L., additional, Paquette, Ronald, additional, Williams, Loretta A., additional, Hehlmann, Rüdiger, additional, Michallet, Mauricette, additional, Gambacorti-Passerini, Carlo, additional, Tang, Derek, additional, DeGutis, Irene S., additional, McBride, Ali, additional, Parsons, Lori, additional, Montelongo, Monica Z., additional, and Mauro, Michael, additional

Published
2022
Full Text
View/download PDF

34. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Author

Cortes-Selva, Diana, primary, Casneuf, Tineke, additional, Vishwamitra, Deeksha, additional, Stein, Sarah, additional, Perova, Tatiana, additional, Skerget, Sheri, additional, Ramos, Elena, additional, van Steenbergen, Laure, additional, De Maeyer, Dries, additional, Boominathan, Rengasamy, additional, Lau, Onsay, additional, Davis, Cuc, additional, Banerjee, Arnob, additional, Stephenson, Tara, additional, Uhlar, Clarissa M., additional, Kobos, Rachel, additional, Goldberg, Jenna D., additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Wu, Liviawati S., additional, Moreau, Philippe, additional, Usmani, Saad, additional, Bahlis, Nizar Jacques, additional, Van De Donk, Niels WCJ, additional, and Verona, Raluca, additional

Published
2022
Full Text
View/download PDF

35. Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Author

Willemin, Marie-Emilie, primary, Wang Lin, Shun Xin, additional, De Zwart, Loeckie, additional, Wu, Liviawati S., additional, Miao, Xin, additional, Verona, Raluca, additional, Banerjee, Arnob, additional, Liu, Baolian, additional, Kobos, Rachel, additional, Qi, Ming, additional, Ouellet, Daniele, additional, Goldberg, Jenna D., additional, and Girgis, Suzette, additional

Published
2022
Full Text
View/download PDF

36. Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Author

Al-Homsi, A Samer, primary, Cirrone, Frank, additional, Cole, Kelli, additional, Suarez-Londono, Jaime Andres, additional, Gardner, Sharon L., additional, Hsu, Jingmei, additional, Wo, Stephanie, additional, Stocker, Kelsey, additional, Bruno, Benedetto, additional, Goldberg, Judith, additional, Levinson, Benjamin, additional, and Abdul-Hay, Maher, additional

Published
2022
Full Text
View/download PDF

37. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Saliba, Antoine N., additional, Shallis, Rory Michael, additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Sacchi De Camargo Correia, Guillerhme, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Bradshaw, Danielle, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

38. Defining Ferritin Clinical Decision Limits to Improve Diagnosis and Treatment of Iron Deficiency: A Modified Delphi Study

Author

Naveed, Kanza, primary, Goldberg, Nicola, additional, Shore, Eliane, additional, Dhoot, Arti, additional, Gabrielson, Denise, additional, Goodarzi, Zahra, additional, Lin, Yulia, additional, Pai, Menaka, additional, Pardy, Natasha A., additional, Robinson, Sue, additional, Andreou, Roseann, additional, Sood, Manish, additional, Price, Victoria, additional, Verduyn, Ashley, additional, Parker, Michelle L., additional, Fralick, Michael, additional, Beriault, Daniel, additional, and Sholzberg, Michelle, additional

Published
2022
Full Text
View/download PDF

40. Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Author

Robinson, Troy, primary, Bowman, Robert L., additional, Persaud, Sonali, additional, Liu, Ying, additional, Gao, Qi, additional, Zhang, Jing-Ping, additional, Sun, Xiaotian, additional, Sciambi, Adam, additional, Llanso, Aaron, additional, Famulare, Christopher, additional, Goldberg, Aaron D, additional, Dogan, Ahmet, additional, Roshal, Mikhail, additional, Levine, Ross L., additional, and Xiao, Wenbin, additional

Published
2022
Full Text
View/download PDF

41. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Author

Wolach, Ofir, primary, Garcia, Jacqueline S., additional, Desai, Pinkal, additional, Vachhani, Pankit, additional, Zeidner, Joshua F., additional, Abedin, Sameem, additional, Sweet, Kendra, additional, Lai, Catherine, additional, Moshe, Yakir, additional, Pollyea, Daniel A., additional, Xavier, Marin, additional, Nachmias, Boaz, additional, Zuckerman, Tsila, additional, Lee, Sangmin, additional, Chen, Evan C., additional, Bathini, Srilakshmi, additional, Edwards, Wesleigh, additional, Bui, Cat N., additional, Cheng, Wei-Han, additional, Miller, Catherine, additional, Guerin, Annie, additional, Maitland, Jessica, additional, Ma, Esprit, additional, Montez, Melissa, additional, Grunspan, Moshe, additional, and Goldberg, Aaron D, additional

Published
2022
Full Text
View/download PDF

43. Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Author

Searle, Emma, primary, Quach, Hang, additional, Wong, Sandy W., additional, Costa, Luciano J., additional, Hulin, Cyrille, additional, Janowski, Wojciech, additional, Berdeja, Jesus, additional, Anguille, Sébastien, additional, Matous, Jeffrey V., additional, Touzeau, Cyrille, additional, Michallet, Anne-Sophie, additional, Husnik, Marla, additional, Vishwamitra, Deeksha, additional, Niu, Zhuolu, additional, Larsen, Julie, additional, Chen, Lingling, additional, Goldberg, Jenna D., additional, Popat, Rakesh, additional, and Spencer, Andrew, additional

Published
2022
Full Text
View/download PDF

44. Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes - a Single Center Longitudinal Cohort Analysis

Author

Fridberg, Gil, primary, Amit, Odelia, additional, Karni, Chen, additional, Tshernichovsy, Dina, additional, Shasha, David, additional, Rouach, Vanessa, additional, Verssano, David, additional, Bar-Shai, Amir, additional, Wasserman, Gilad, additional, Goldberg, Ilan, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

46. Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Author

Chari, Ajai, primary, Touzeau, Cyrille, additional, Schinke, Carolina, additional, Minnema, Monique C., additional, Berdeja, Jesus, additional, Oriol, Albert, additional, Van De Donk, Niels WCJ, additional, Rodriguez Otero, Paula, additional, Askari, Elham, additional, Mateos, Maria-Victoria, additional, Costa, Luciano J., additional, Caers, Jo, additional, Rasche, Leo, additional, Krishnan, Amrita Y., additional, Vishwamitra, Deeksha, additional, Ma, Xuewen, additional, Qin, Xiang, additional, Gries, Katharine S., additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Goldberg, Jenna D., additional, Heuck, Christoph, additional, San-Miguel, Jesús, additional, and Moreau, Philippe, additional

Published
2022
Full Text
View/download PDF

47. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

Author

Isabelle S. Csete, Ross L. Levine, Qi Gao, Alexander Chan, Andriy Derkach, Maximilian Stahl, Sheng F. Cai, Jinjuan Yao, Tanmay Mishra, Richard Koche, Sophia Yanis, Martin S. Tallman, Aaron D Goldberg, Michael R. Waarts, Raajit K. Rampal, Ahmet Dogan, Robert L. Bowman, Minal Patel, Ying Liu, Wenbin Xiao, Mikhail Roshal, Maria E. Arcila, Jeeyeon Baik, Nicole L. DelGaudio, Christopher Famulare, and Yanming Zhang

Subjects
Adult, Male, Myeloid, medicine.medical_treatment, Immunology, Chronic myelomonocytic leukemia, macromolecular substances, Plasmacytoid dendritic cell, Biology, Biochemistry, Targeted therapy, chemistry.chemical_compound, hemic and lymphatic diseases, medicine, Humans, neoplasms, Aged, Myeloid leukemia, hemic and immune systems, Dendritic Cells, Cell Biology, Hematology, Middle Aged, medicine.disease, Leukemia, Myeloid, Acute, Leukemia, medicine.anatomical_structure, RUNX1, chemistry, Core Binding Factor Alpha 2 Subunit, Mutation, Cancer research, Female, Interleukin-3 receptor, Blast Crisis, BLOOD Commentary
Abstract

Plasmacytoid dendritic cells (pDCs) are the principal natural type I interferon–producing dendritic cells. Neoplastic expansion of pDCs and pDC precursors leads to blastic plasmacytoid dendritic cell neoplasm (BPDCN), and clonal expansion of mature pDCs has been described in chronic myelomonocytic leukemia. The role of pDC expansion in acute myeloid leukemia (AML) is poorly studied. Here, we characterize patients with AML with pDC expansion (pDC-AML), which we observe in ∼5% of AML cases. pDC-AMLs often possess cross-lineage antigen expression and have adverse risk stratification with poor outcome. RUNX1 mutations are the most common somatic alterations in pDC-AML (>70%) and are much more common than in AML without pDC expansion and BPDCN. We demonstrate that pDCs are clonally related to, as well as originate from, leukemic blasts in pDC-AML. We further demonstrate that leukemic blasts from RUNX1-mutated AML upregulate a pDC transcriptional program, poising the cells toward pDC differentiation and expansion. Finally, tagraxofusp, a targeted therapy directed to CD123, reduces leukemic burden and eliminates pDCs in a patient-derived xenograft model. In conclusion, pDC-AML is characterized by a high frequency of RUNX1 mutations and increased expression of a pDC transcriptional program. CD123 targeting represents a potential treatment approach for pDC-AML.

Published
2021

48. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia

Author

Goldberg, Liat, Tijssen, Marloes R., Birger, Yehudit, Hannah, Rebecca L., Kinston, Sarah J., Schütte, Judith, Beck, Dominik, Knezevic, Kathy, Schiby, Ginette, Jacob-Hirsch, Jasmine, Biran, Anat, Kloog, Yoel, Marcucci, Guido, Bloomfield, Clara D., Aplan, Peter D., Pimanda, John E., Göttgens, Berthold, and Izraeli, Shai

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results